{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T22:55:37Z","timestamp":1763765737283},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1007\/s00432-008-0440-0","type":"journal-article","created":{"date-parts":[[2008,6,30]],"date-time":"2008-06-30T12:00:23Z","timestamp":1214827223000},"page":"53-59","source":"Crossref","is-referenced-by-count":28,"title":["Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U)"],"prefix":"10.1007","volume":"135","author":[{"given":"Jun-ichi","family":"Kitagawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Tsurumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoe","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Kanemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senji","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahito","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Takami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisataka","family":"Moriwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,7,1]]},"reference":[{"key":"440_CR1","first-page":"1921","volume":"96","author":"C Adida","year":"2000","unstructured":"Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J et al (2000) Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 96:1921\u20131925","journal-title":"Blood"},{"key":"440_CR2","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1084\/jem.158.6.1895","volume":"158","author":"DA Cantrell","year":"1983","unstructured":"Cantrell DA, Smith KA (1983) Transient expression of interleukin 2 receptors. Consequences for T cell growth. J Exp Med 158:1895\u20131911. doi: 10.1084\/jem.158.6.1895","journal-title":"J Exp Med"},{"key":"440_CR3","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244\u20131253","journal-title":"J Clin Oncol"},{"key":"440_CR4","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A Gallamini","year":"2004","unstructured":"Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, Morabito F, Martelli M, Brusamolino E, Iannitto E, Zaja F, Cortelazzo S, Rigacci L, Devizzi L, Todeschini G, Santini G, Brugiatelli M, Federico M (2004) Intergruppo Italiano Linfomi. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103:2474\u20132479. doi: 10.1182\/blood-2003-09-3080","journal-title":"Blood"},{"key":"440_CR5","first-page":"76","volume":"92","author":"C Gisselbrecht","year":"1998","unstructured":"Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Bri\u00e8re J, Haioun C et al (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin\u2019s lymphomas. Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte (GELA). Blood 92:76\u201382","journal-title":"Blood"},{"key":"440_CR6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00432-004-0600-9","volume":"131","author":"H Goto","year":"2005","unstructured":"Goto H, Tsurumi H, Takemura M, Ino-Shimomura Y, Kasahara S, Sawada M et al (2005) Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin\u2019s lymphoma: in combination with the International Prognostic Index. J Cancer Res Clin Oncol 131:73\u201379. doi: 10.1007\/s00432-004-0600-9","journal-title":"J Cancer Res Clin Oncol"},{"key":"440_CR7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1600-0609.2006.00702.x","volume":"77","author":"N Goto","year":"2006","unstructured":"Goto N, Tsurumi H, Takemura M, Hara T, Sawada M, Kasahara S et al (2006) Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin\u2019s lymphoma. Eur J Haematol 77:217\u2013225. doi: 10.1111\/j.1600-0609.2006.00702.x","journal-title":"Eur J Haematol"},{"key":"440_CR8","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1200\/JCO.1997.15.3.1131","volume":"15","author":"C Haioun","year":"1997","unstructured":"Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P et al (1997) Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin\u2019s lymphoma: updated results of the prospective study LNH87\u20132. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol 15:1131\u20131137","journal-title":"J Clin Oncol"},{"key":"440_CR9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/1096-8652(200008)64:4<257::AID-AJH4>3.0.CO;2-2","volume":"64","author":"T Hara","year":"2000","unstructured":"Hara T, Tsurumi H, Takemura M, Goto H, Yamada T, Sawada M et al (2000) Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin\u2019s lymphoma. Am J Hematol 64:257\u2013261. doi:10.1002\/1096-8652(200008)64:4<257::AID-AJH4>3.0.CO;2-2","journal-title":"Am J Hematol"},{"key":"440_CR10","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","volume":"17","author":"NL Harris","year":"1999","unstructured":"Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835\u20133849","journal-title":"J Clin Oncol"},{"key":"440_CR11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJM199708213370804","volume":"337","author":"A Ichikawa","year":"1997","unstructured":"Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K et al (1997) Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337:529\u2013534. doi: 10.1056\/NEJM199708213370804","journal-title":"N Engl J Med"},{"key":"440_CR12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3109\/10428199809059228","volume":"31","author":"E Legouffe","year":"1998","unstructured":"Legouffe E, Rodriguez C, Picot MC, Richard B, Klein B, Rossi JF et al (1998) C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin\u2019s lymphoma. Leuk Lymphoma 31:351\u2013357","journal-title":"Leuk Lymphoma"},{"key":"440_CR13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/mpo.2950220410","volume":"22","author":"AA Miller","year":"1994","unstructured":"Miller AA, Salewski E (1994) Prospects for pirarubicin. Med Pediatr Oncol 22:261\u2013268. doi: 10.1002\/mpo.2950220410","journal-title":"Med Pediatr Oncol"},{"key":"440_CR14","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1182\/blood.V94.10.3541.422k15_3541_3550","volume":"94","author":"N Niitsu","year":"1999","unstructured":"Niitsu N, Okabe-Kado J, Kasukabe T, Yamamoto-Yamaguchi Y, Umeda M, Honma Y (1999) Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin\u2019s lymphoma. Blood 94:3541\u20133550","journal-title":"Blood"},{"key":"440_CR15","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood.V97.5.1202","volume":"97","author":"N Niitsu","year":"2001","unstructured":"Niitsu N, Okamoto M, Okabe-Kado J, Takagi T, Yoshida T, Aoki S et al (2001) Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma. Blood 97:1202\u20131210. doi: 10.1182\/blood.V97.5.1202","journal-title":"Blood"},{"key":"440_CR16","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.leu.2402699","volume":"17","author":"N Niitsu","year":"2003","unstructured":"Niitsu N, Honma Y, Iijima K, Takagi T, Higashihara M, Sawada U et al (2003) Clinical significance of nm23-H1 proteins expressed on cell surface in non-Hodgkin\u2019s lymphoma. Leukemia 17:196\u2013202. doi: 10.1038\/sj.leu.2402699","journal-title":"Leukemia"},{"key":"440_CR17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.1365-2141.1996.4641003.x","volume":"93","author":"K Ogata","year":"1996","unstructured":"Ogata K, Yokose N, An E, Kamikubo K, Tamura H, Dan K et al (1996) Plasma soluble interleukin-2 receptor level in patients with primary myelodysplastic syndromes: a relationship with disease subtype and clinical outcome. Br J Haematol 93:45\u201352. doi: 10.1046\/j.1365-2141.1996.4641003.x","journal-title":"Br J Haematol"},{"key":"440_CR18","doi-asserted-by":"crossref","first-page":"186","DOI":"10.7326\/0003-4819-127-3-199708010-00002","volume":"127","author":"HA Preti","year":"1997","unstructured":"Preti HA, Cabanillas F, Talpaz M, Tucker SL, Seymour JF, Kurzrock R (1997) Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med 127:186\u2013194","journal-title":"Ann Intern Med"},{"key":"440_CR19","first-page":"37","volume":"1","author":"RJ Robb","year":"1982","unstructured":"Robb RJ (1982) Human T-cell growth factor: purification and interaction with a cellular receptor. Lymphokine Res 1:37\u201343","journal-title":"Lymphokine Res"},{"key":"440_CR20","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.4049\/jimmunol.135.5.3172","volume":"135","author":"LA Rubin","year":"1985","unstructured":"Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R et al (1985) Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135:3172\u20133177","journal-title":"J Immunol"},{"key":"440_CR21","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1182\/blood.V94.10.3334.422k18_3334_3339","volume":"94","author":"P Salven","year":"1999","unstructured":"Salven P, Teerenhovi L, Joensuu H (1999) A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin\u2019s lymphoma. Blood 94:3334\u20133339","journal-title":"Blood"},{"key":"440_CR22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1034\/j.1600-0609.2000.065003195.x","volume":"65","author":"K Sasaki","year":"2000","unstructured":"Sasaki K, Niitsu N (2000) Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin\u2019s lymphoma. Eur J Haematol 65:195\u2013202. doi: 10.1034\/j.1600-0609.2000.065003195.x","journal-title":"Eur J Haematol"},{"key":"440_CR23","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1034\/j.1600-0609.2002.01654.x","volume":"68","author":"M Sawada","year":"2002","unstructured":"Sawada M, Tsurumi H, Yamada T, Hara T, Fukuno K, Goto H et al (2002) A prospective study of P-IMVP-16\/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin\u2019s lymphoma who had previously received CHOP therapy as first-line chemotherapy. Eur J Haematol 68:354\u2013361. doi: 10.1034\/j.1600-0609.2002.01654.x","journal-title":"Eur J Haematol"},{"key":"440_CR24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.1999.17.1.423","volume":"17","author":"MA Shipp","year":"1999","unstructured":"Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M et al (1999) International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin\u2019s lymphomas: report of the jury. J Clin Oncol 17:423\u2013429","journal-title":"J Clin Oncol"},{"key":"440_CR25","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1365-2141.1994.tb05116.x","volume":"88","author":"R Stasi","year":"1994","unstructured":"Stasi R, Zinzani PL, Galieni P, Lauta VM, Damasio E, Dispensa E et al (1994) Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin\u2019s lymphoma. Br J Haematol 88:770\u2013777. doi: 10.1111\/j.1365-2141.1994.tb05116.x","journal-title":"Br J Haematol"},{"key":"440_CR26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF00253970","volume":"20","author":"T Takagi","year":"1987","unstructured":"Takagi T, Oguro M (1987) (2\u2033-R)-4\u2032-o-tetrahydropyranyladriamycin, a new anthracycline derivative; its effectiveness in lymphoid malignancies. Cancer Chemother Pharmacol 20:151\u2013154. doi: 10.1007\/BF00253970","journal-title":"Cancer Chemother Pharmacol"},{"key":"440_CR27","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","unstructured":"The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med 329:987\u2013994. doi: 10.1056\/NEJM199309303291402","journal-title":"N Engl J Med"},{"key":"440_CR28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00432-003-0508-9","volume":"130","author":"H Tsurumi","year":"2004","unstructured":"Tsurumi H, Yamada T, Sawada M, Kasahara S, Kanemura N, Kojima Y et al (2004) Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin\u2019s lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol 130:107\u2013113. doi: 10.1007\/s00432-003-0508-9","journal-title":"J Cancer Res Clin Oncol"},{"key":"440_CR29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/hon.815","volume":"25","author":"H Tsurumi","year":"2007","unstructured":"Tsurumi H, Hara T, Goto N, Kanemura N, Kasahara S, Sawada M et al (2007) A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70\u00a0years or older with diffuse large B-cell lymphoma. Hematol Oncol 25:107\u2013114. doi: 10.1002\/hon.815","journal-title":"Hematol Oncol"},{"key":"440_CR30","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/archderm.1996.03890250052009","volume":"132","author":"MA Wasik","year":"1996","unstructured":"Wasik MA, Vonderheid EC, Bigler RD, Marti R, Lessin SR, Polansky M et al (1996) Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications. Arch Dermatol 132:42\u201347. doi: 10.1001\/archderm.132.1.42","journal-title":"Arch Dermatol"},{"key":"440_CR31","first-page":"171","volume":"82","author":"F Zaja","year":"1997","unstructured":"Zaja F, Russo D, Silvestri F, Fanin R, Damiani D, Infanti L et al (1997) Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and outcome. Haematologica 82:171\u2013177","journal-title":"Haematologica"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-008-0440-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-008-0440-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-008-0440-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T01:07:40Z","timestamp":1684458460000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-008-0440-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["440"],"URL":"https:\/\/doi.org\/10.1007\/s00432-008-0440-0","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,1]]}}}